ABSTRACT
Gastric cancer is one of the common digestive tract malignant tumors. Locally advanced gastric cancer has a large tumor load, mostly small metastatic lesions, and a high risk of recurrence. The comprehensive treatment strategy of "radical operation with D 2 lymph node dissec-tion and perioperative treatment" has gradually become the standard treatment mode for locally advanced gastric cancer. In recent years, there have been breakthroughs in perioperative treatment of locally advanced gastric cancer by radiotherapy, targeted therapy and especially immunotherapy. In this article, the authors analyze the research progress of perioperative treatment of locally advanced gastric cancer at home and abroad, systematically describe the current status and prospect of perioperative treatment of locally advanced gastric cancer.
ABSTRACT
Aim To evaluate whether the combination of polypeptide AP25 and docetaxel is more efficient in treating experimental breast cancer,than either reagent used alone,and to offer suggestions for clinical use. Methods An experimental breast carcinoma model was set up to investigate the anti-tumor effects of AP25 and docetaxel combination.The Q value was caluculat-ed by Guinness rules and the anti-tumor effects of the combination of polypeptide AP25 and docetaxel were e-valuated.Results The treatment by the combination of polypeptide AP25 and docetaxel showed a better tumor inhibition rate.The combination of AP25 20 mg ·kg -1 and docetaxel 10 mg·kg -1 significantly inhibi-ted the tumor growth with 0.85 1.15,showing a synergistic effect.Conclusions The combination of AP25 and docetaxel can significantly in-hibit the tumor growth with a synergistic effect and de-crease the dose of chemotherapy.